Integrating Metabolomics, Histopathology, and Cardiac Marker Analysis to Assess Valsartan's Efficacy in Mitigating Dasatinib-Induced Cardiac Toxicity in Sprague-Dawley Rats
Khalid Alhazzani,Hanan Mohammed,Mohammad Algahtani,Khaldoon Aljerian,Ali Alhoshani,Homood As Sobeai,Syed Ahamad,Moureq Alotaibi,Abdullah Alhamed,Fawaz Alasmari,Mohammed Alqinyah,Hussain Alhamami,Ahmed Alanazi
DOI: https://doi.org/10.2147/dddt.s497212
IF: 4.3188
2024-12-06
Drug Design Development and Therapy
Abstract:Khalid Alhazzani, 1 Hanan Mohammed, 1 Mohammad M Algahtani, 1 Khaldoon Aljerian, 2 Ali Alhoshani, 1 Homood M As Sobeai, 1 Syed Rizwan Ahamad, 3 Moureq R Alotaibi, 1 Abdullah S Alhamed, 1 Fawaz Alasmari, 1 Mohammed Alqinyah, 1 Hussain N Alhamami, 1 Ahmed Z Alanazi 1 1 Department of Pharmacology & Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 2 Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 3 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia Correspondence: Ahmed Z Alanazi, Department of Pharmacology & Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia, Email Background: Dasatinib (DASA) is associated with cardiotoxic effects, posing risks to patients. Valsartan (VAL) may offer protective benefits against these effects. This study evaluates the impact of DASA, VAL, and their combination on cardiac health. Methods: Wistar rats were treated with DASA, VAL, and a combination of VAL and DASA intraperitoneally every other day for 14 days. Body weight and survival rates were monitored. Serum levels of cardiac biomarkers (CPK, LDH, AST) were analyzed. Histopathological and immunohistochemical analyses assessed myocardial architecture and apoptosis-related protein expression. Metabolomic profiling was conducted using GC-MS to identify metabolic changes across treatment groups. Results: The DASA group experienced significant weight loss and a 50% mortality rate, while the combination group had no mortality. Cardiac biomarkers like CPK, LDH, and AST were elevated in the DASA group but significantly reduced in the VAL + DASA group. Histopathological examination showed significant myocardial injury in the DASA group, with improved cardiac tissue morphology in the combination group. Immunohistochemical analysis revealed altered expression of apoptosis-related proteins, including caspase-3 and BCL-2, with improved levels in the combination group compared to DASA alone. Metabolomic profiling identified significant metabolic shifts, with 15 metabolites differentiating the treatment groups, and the VAL + DASA group mitigated the metabolic disturbances caused by DASA. Conclusion: The study suggesting VAL's potential therapeutic role in managing DASA-induced cardiac toxicity. The combination of VAL with DASA not only improved survival rates and reduced cardiac biomarker levels but also preserved myocardial architecture and normalized metabolic profiles. These findings highlight the importance of integrated approaches in evaluating drug efficacy and suggest VAL as a promising candidate for protecting cardiac function in preclinical models of DASA therapy. Keywords: cardiac toxicity, dasatinib, valsartan, metabolomics, histopathology Cardiovascular disease remains the leading cause of mortality among long-term cancer survivors, a demographic that continues to grow despite the advances in cancer treatment. 1 Among the various treatments, targeted chemotherapeutic agents, particularly small-molecule tyrosine kinase inhibitors (TKIs), have been pivotal in improving cancer outcomes. However, these agents are associated with toxic side effects. Despite their design to selectively target cancer cells and minimize collateral damage to healthy cells, TKIs have been implicated in the development of cardiomyopathies. 2 The cardiotoxic effects of TKIs, including hypertrophy, heart failure, and myocardial infarction, pose significant challenges in the management of cancer patients. 3 Dasatinib (DASA), an oral TKI, has shown substantial efficacy in targeting BCR-ABL, Src family kinases, c-Kit, and platelet-derived growth factor receptors, making it a valuable treatment option for certain leukemias and solid tumors. Specifically, DASA is approved for use in chronic lymphocytic leukemia (CLL) patients who are intolerant or refractory to imatinib, as well as in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients. 4,5 Despite its therapeutic benefits, DASA is associated with significant adverse effects, notably cardiotoxicity. The mechanisms driving DASA-induced cardiotoxicity are not fully understood, but current research points to the involvement of apoptosis induction, inhibition of pro-survival pathways, and other cellular mechanisms. 6,7 It is crucial to explore cardioprotective drugs that can mitigate the cardiotoxicity associated with DASA. Valsartan (VAL), an angiotensin-receptor blocker, has demonstrated protective effects against cardiovascular diseas -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal